Download App

Log in to access Online Inquiry
Company Overview More
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and elivaldogene autotemcel to treat cerebral adrenoleukodystrophy. The company’s clinical study program includes HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with β-thalassemia. It has strategic collaboration and license agreements with Orchard Therapeutics Limited, Forty Seven, Inc., and Magenta Therapeutics, Inc. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Cambridge, Massachusetts.
CEO: Obenshain, Andrew
Market: NASDAQ
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

Moomoo > Quotes > BLUE bluebird bio > Detailed Quotes

BLUE bluebird bio

3.200-0.070-2.14%
Close 05/23 20:00 ET
High
3.335
Open
3.320
Turnover
3.99M
Low
3.180
Pre Close
3.270
Volume
1.23M
Market Cap
228.65M
P/E(TTM)
Loss
52wk High
23.038
Shares
71.45M
P/E(Static)
Loss
52wk Low
3.080
Float Cap
226.47M
Bid/Ask %
-73.33%
Historical High
152.883
Shs Float
70.77M
Volume Ratio
0.59
Historical Low
3.080
Dividend TTM
--
Div Yield TTM
450
P/B
0.87
Dividend LFY
--
Div Yield LFY
14062.50%
Turnover Ratio
1.74%
Amplitude
4.74%
Avg Price
3.241
Lot Size
1
Float Cap
226.47M
Bid/Ask %
-73.33%
Historical High
152.883
Shs Float
70.77M
Volume Ratio
0.59
Historical Low
3.080
Dividend TTM
--
P/B
0.87
Dividend LFY
--
Turnover Ratio
1.74%
Amplitude
4.74%
Avg Price
3.241
Lot Size
1
Price Forecast

No Data

News

Comment